Pharmaceuticals News and Research

RSS

Karolinska Institutet scientists discover new approach to treat type II diabetes

An international team of scientists, led from Karolinska Institutet in Sweden, have discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

27 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

Alitair receives U.S. patent allowance for ion exchange resin formulation of benzonatate

Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate.

27 Sep 2012

Accenture acquires Octagon Research Solutions

Accenture has completed its acquisition of Octagon Research Solutions, Inc., a provider of clinical and regulatory information management solutions and software for the pharmaceutical industry based in Wayne, Pa. The acquisition was announced on Aug. 2.

26 Sep 2012

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. District Court of the District of Massachusetts has ruled in favor of Alnylam and has denied Tekmira Pharmaceuticals Corporation's motion to dismiss certain claims and motion to disqualify Alnylam's counsel in an infringement suit filed in January 2012.

26 Sep 2012

UCSD bioengineers to play a central role in new NIH program to accelerate metabolomics

With a $6 million grant over five years, bioengineers from the University of California, San Diego will play a central role in a new program from the National Institutes of Health (NIH) to accelerate "metabolomics", an emerging field of biomedical research that offers a path to a wealth of information about a person's nutrition, infection, health, disease status and more.

25 Sep 2012

Public, private sectors must engage to increase chances of success in fighting NCDs

"Some academics and non-profit organizations are skeptical of the motives of the increasing number of multinational companies who seek partnerships to address non-communicable diseases (NCDs)," Derek Yach, senior vice president of global health and agriculture policy at PepsiCo and former head of NCDs at WHO, writes in the Huffington Post's "Impact" blog.

25 Sep 2012

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma

There are many different chronic respiratory diseases. Verona Pharma is mainly focused on two diseases: asthma and COPD. Asthma is a very common disease and unfortunately it has been increasing in prevalence in developed countries. This is the same with COPD; however, there may be different reasons for this.

25 Sep 2012

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.

25 Sep 2012

Wiley announces publication of 6-volume Encyclopedia of Drug Metabolism and Interactions

Wiley is pleased to announce publication of the state-of-the-art, 6-volume Encyclopedia of Drug Metabolism and Interactions.

25 Sep 2012

Wiley publishes 6th Edition of Patty's Toxicology

The expanded 6th Edition of the cornerstone reference work on occupational health and toxicology is now published by Wiley. Patty's Toxicology, 6th Edition, 6-Volume Set updates its comprehensive coverage and adds chapters to reflect the changing and expanding field of Toxicology.

25 Sep 2012

SCIOinspire unveils new company name

SCIOinspire Corp., which has served the healthcare marketplace since 2008, today unveiled a new name that reflects its current core focus and corporate identity.

25 Sep 2012

pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.

25 Sep 2012

Senate Working Group on Malaria expands to congressional caucus including NTDs

"A bipartisan pair of senators is expanding an existing working group on malaria issues to become a congressional caucus that will focus on efforts to combat 17 tropical diseases including malaria," CQ HealthBeat reports.

24 Sep 2012

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the execution of the licensing agreement with Vestiq Pharmaceuticals to commercialize Oravig in the United States for the treatment of oropharyngeal candidiasis in adults.

24 Sep 2012

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that dosing with their first drug in its first Phase 1 study, was completed last week.

24 Sep 2012

Sanofi chooses OnPoint clinical trial management system from BioClinica

BioClinica, Inc., a global provider of clinical trial management services, announced today that Sanofi, one of the world's largest pharmaceutical companies, has selected BioClinica's OnPoint as the company's standard CTMS (Clinical Trial Management System).

From Clario 24 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

Pharmaceuticals News and Research

Karolinska Institutet scientists discover new approach to treat type II diabetes

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Alitair receives U.S. patent allowance for ion exchange resin formulation of benzonatate

Accenture acquires Octagon Research Solutions

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

UCSD bioengineers to play a central role in new NIH program to accelerate metabolomics

Public, private sectors must engage to increase chances of success in fighting NCDs

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Wiley announces publication of 6-volume Encyclopedia of Drug Metabolism and Interactions

Wiley publishes 6th Edition of Patty's Toxicology

SCIOinspire unveils new company name

pSivida reports revenues of $699,000 for fourth quarter 2012

Senate Working Group on Malaria expands to congressional caucus including NTDs

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

Sanofi chooses OnPoint clinical trial management system from BioClinica

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence